AAN 2024 | Skin biopsies for synucleinopathies: key research questions
Christopher Gibbons, MD, FAAN, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, addresses unresolved issues concerning the diagnosis of synucleinopathies using alpha-synuclein quantification in skin biopsies. Most studies to date have concentrated on patients with an established disease diagnosis. Dr Gibbons stresses the importance of future studies focusing on individuals at risk of developing the disease before its onset. Ongoing trials are examining individuals with mild cognitive impairment (MCI) and REM sleep behavior disorder, believed to be prodromal to synucleinopathies, to determine if analyzing alpha-synuclein in the skin can predict future disease development. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Gibbons has received personal compensation for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Autonomic Neuroscience. Dr Gibbons has stock in CND Life Sciences. Dr Gibbons has received publishing royalties from a publication relating to health care. Dr Gibbons has received personal compensation for serving as a Expert Advisor with Department of Justice.
